Jeong et al. (2020) [111] developed a novel VV construct (NOV) co-expressing TRAIL and angiopoietin-1 (Ang1), replacing viral thymidine kinase (vTK) and vaccinia growth factor (VGF) to enhance tumor selectivity and reduce off-target effects. The gene discussed is ANGPT1; the disease is neoplasm.